DepCy: Depressive Symptoms and Subjective Stress in the Course of the Menstrual Cycle - an Ambulatory Assessment Study.

Sponsor
Freie Universität Berlin (Other)
Overall Status
Recruiting
CT.gov ID
NCT04086316
Collaborator
(none)
74
1
35.5
2.1

Study Details

Study Description

Brief Summary

Background:

Major changes in female sex hormone concentrations influence the development of depressive symptoms in women. This hypothesis has been thoroughly investigated with regard to the menopause, the postpartal phase and also premenstrual dysphoric disorder. However, much less is known regarding the impact of female sex hormone fluctuations on depression during the regular menstrual cycle. There are indications that during the luteal phase, women might be more vulnerable to the development of depressive symptoms, while during the follicular phase and at ovulation, hormone concentrations might present a protective factor against depressive symptomatology. Subjective stress could mediate the relationship between depressive symptom development and the menstrual cycle phases. The complex interaction between sex hormones and psychological symptoms in the course of menstrual cycle phases is still understudied.

Method:

74 women (37 with and 37 without current depressive episode), will take part in a smartphone-based ambulatory assessment. Women will provide daily ratings of depressive symptoms and perceived stress for a period of one menstrual cycle (approx. 26-30 days). Three menstrual cycle phases will be assessed - the follicular phase, ovulation and the luteal phase. An ambulatory assessment will be used for these daily assessments. To assess the menstrual cycle phase participants will use ovulation tests on five days in the late follicular phase.

The following research questions will be investigated:

Research question 1: Do depressive symptoms (number and severity) change in the course of the menstrual cycle within the two groups? Research question 2: Which depressive symptoms are particularly sensitive to changes in the course of the menstrual cycle phases? Research question 3: Does the subjective stress change in the course of the menstrual cycle within the two groups? Research question 4: Are there differences between depressive and healthy women in terms of changes in depressive symptoms and subjective stress experience?

Implications:

The aim of the study is to investigate women-specific psychobiological factors influencing depression. Therefore, fluctuations in depressive symptoms and subjective stress experience will be investigated as a function of the respective menstrual cycle phases. The identification of cycle phases associated with increased or reduced vulnerability to depressive symptoms will support the development of women-specific prevention and treatment programs.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    74 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Vulnerable and Resilient Phases During the Menstrual Cycle and Their Influence on Depressive Symptoms and Stress. An Ambulatory Assessment Study on Healthy Women and Women With Depression.
    Actual Study Start Date :
    Jan 15, 2020
    Actual Primary Completion Date :
    Apr 15, 2021
    Anticipated Study Completion Date :
    Dec 30, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    Depression Group

    Naturally cycling women with a major depressive episode, assessed by Structured Clinical Interview for DSM-5 (SCID Clinical Version)

    Healthy Group

    Naturally cycling women without a major depressive episode, assessed by Structured Clinical Interview for DSM-5 (SCID Clinical Version)

    Outcome Measures

    Primary Outcome Measures

    1. Changes in Depressive Symptoms between the menstrual cycle phases [Depressive Symptoms will be assessed daily with an ambulatory assessment for the duration of one menstrual cycle (approx. 28 days).]

      Depressive Symptoms will be measured with the Patient Health Questionnaire (PHQ-9), which will be adapted for the ambulatory assessment use (e.g. changing "in the last two weeks" to "right now").

    2. Changes in subjective stress (self report) between the menstrual cycle phases [Subjective stress will be assessed daily with an ambulatory assessment for the duration of one menstrual cycle (approx. 28 days).]

      Stress Symptoms will be measured with the short Version of the Perceived Stress Scale (PSS-4), which will be adapted for the ambulatory assessment use (e.g. changing "in the last two weeks" to "right now").

    Secondary Outcome Measures

    1. Differences between women with and without a Major depressive Episode [Depressive Symptoms will be assessed daily with an ambulatory assessment for the duration of one menstrual cycle (approx. 28 days).]

      Differences between women with and without a Major depressive Episode (measured with the SCID-CV)

    2. Differences between women with and without a Major depressive Episode [Subjective stress will be assessed daily with an ambulatory assessment for the duration of one menstrual cycle (approx. 28 days).]

      Differences between women with and without a Major depressive Episode (measured with the SCID-CV)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    For participants with major depressive episode:
    Inclusion criteria:
    • female sex

    • current diagnosis of a major depression episode

    • minimum age of 18 years

    • regular menstrual cycle.

    Exclusion criteria:
    • Pregnancy less than one year ago;

    • women who are breastfeeding;

    • bipolar disorder;

    • acute suicidal tendencies;

    • schizophrenic disorders (F20-29);

    • substance use disorders

    • psychotropic drugs in the last six months;

    • chronic somatic diseases.

    For participants without major depressive episode:
    Inclusion criteria:
    • female sex;

    • minimum age of 18 years;

    • regular menstrual cycle.

    Exclusion criteria:
    • current or lifetime mental disorder;

    • pregnancy less than one year ago;

    • women who are breastfeeding;

    • psychotropic drugs in the last six months;

    • chronic somatic diseases.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Freie Universität Berlin Berlin Germany 14195

    Sponsors and Collaborators

    • Freie Universität Berlin

    Investigators

    • Principal Investigator: Sarah Schumacher, PhD, Freie Universität Berlin

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Dr. Sarah Schumacher, Postdoctoral researcher, Freie Universität Berlin
    ClinicalTrials.gov Identifier:
    NCT04086316
    Other Study ID Numbers:
    • CycleDepression
    First Posted:
    Sep 11, 2019
    Last Update Posted:
    Aug 15, 2022
    Last Verified:
    Aug 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Dr. Sarah Schumacher, Postdoctoral researcher, Freie Universität Berlin
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 15, 2022